Precision BioSciences, Inc. - Common Stock – Cashflow (NASDAQ:DTIL)

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -87.39 M-10.85 M-45.75 M-84.11 M-58.45 M-65.84 M -58.73 M Mittelzufluss aus Investitionstätigkeit -5.03 M-5.8 M-3.32 M5.83 M-215 K-634 K -434 K Zahlungsströme aus der Finanzierungstätigkeit 1.33 M70.52 M94.98 M5.39 M50.45 M95.16 M 85.22 M Freier Cashflow -92.42 M-15.91 M-49.07 M-86.07 M-58.7 M-65.93 M -58.77 M

Precision BioSciences, Inc. - Common Stock

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

DTIL

Financials

Precision BioSciences, Inc. - Common Stock

Nachrichten

Precision BioSciences, Inc. (DTIL) Discusses Updates on PBG and HBV Program and ELIMINATE-B Trial Results - Slideshow (NASDAQ:DTIL) 2026-05-27

Hepatitis-B-Studiendaten beflügeln Aktie von Precision BioSciences

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates

Precision BioSciences startet Patientenrekrutierung für Gentherapiestudie bei Duchenne-Muskeldystrophie

Precision BioSciences stellt Daten zur Gentherapie für Duchenne-Muskeldystrophie vor

AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?

Jones Trading startet Coverage für Precision BioSciences mit Kaufempfehlung

Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Should You Buy Precision BioSciences (DTIL) After Golden Cross?

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call - Slideshow (NASDAQ:DTIL) 2026-03-18